As per CSR Zeta Pharma maintain its role in raising awareness among healthcare providers regarding relation between Covid-19 and thrombosis and how to deal with,
An interview with Professor Dr. / Hisham Salah Al-Din, Professor of Cardiovascular Medicine at Al Kasr-Aini . Entitled “COVID-19 and Hypercoagulability”.
Why Coronavirus disease-2019, a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic diseases?
2. What are the best practices and recommendations to manage the thrombotic events with COVID-19 patients?
Hesham Salah Eldin MD, FCCP, FACC,
FSCAIProfessor of Cardiology Cathlab Director Faculty of Medicine – Cairo University
Fellow of American College of CardiologyFellow of Society of Cardiovascular Angiography & Intervention
President of Working Group on Dyslipidemia & Atheroscleros is Founder of Egyptian CPR league.
COVID-19 and Hypercoagulability
